secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2026-06-10T21:04:43+00:00
Accession:  0001193125-26-266027
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax issues $250M of 2.25% convertible notes due 2031, net proceeds ~$243M
----------------------------------------------------------------------------

- Issued $250M aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in private placement.
- Net proceeds of approximately $243M after placement agent fees and expenses.
- Proceeds to be used for general corporate purposes including R&D, commercialization, and business development.
- Initial maximum conversion of 13,631,400 shares of common stock (conversion rate 54.5256 shares per $1,000).
- Notes and conversion shares unregistered; issued under Section 4(a)(2) exemption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526266027/0001193125-26-266027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526266027/d105044d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-266027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer